William J. Muller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
William J. Muller has a total of 439 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Gonzalez
Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, USA
6 shared publications - Stephen J. Balevic
Department of Pediatrics Duke University Durham NC USA
6 shared publications - Taylor Heald-Sargent
Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital of Chicago , Chicago, IL
6 shared publications - Amira Al‐Uzri
Oregon Health and Science University, Portland, USA
5 shared publications Sarah J. Kopp
Department of Microbiology–Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois
5 shared publications- Chi Dang Hornik
Department of Pediatrics, Duke University School of Medicine, Durham, USA
4 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Outcomes After Respiratory Virus Detection Prior to Pediatric Solid Organ Transplantation
Background: Respiratory viral infections are associated with increased pulmonary morbidity in immunocompromised populations. It is not known whether pediatric solid organ transplant (SOT) recipients who test positive for respiratory viruses prior to transplant have increased risk of adverse pulmonary outcomes. Methods: We conducted a single‐center retrospective study of pediatric SOT recipients tested for respiratory viruses by multiplex PCR in the 30 days prior to their transplant. Results: Fourteen of 45 recipients who were tested had a virus identified, one of whom tested negative on a subsequent repeat test prior to transplant. The remaining 13 were matched 1:2 to control transplant recipients matched by age at transplant, organ transplanted, and date of transplant. No differences in adverse pulmonary outcomes were identified up to 90 days post‐SOT. A similar comparison of patients testing positive to 31 patients with negative respiratory virus testing also did not identify any differences in adverse pulmonary outcomes. Conclusions: Among pediatric SOT recipients who underwent clinically indicated respiratory viral testing within 30 days prior to transplant, we did not observe a clear excess of post‐transplant pulmonary morbidity. Larger multicenter studies are needed to confirm this observation.
- 6 November 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11)
Open AccessOutcomes After Respiratory Virus Detection Prior to Pediatric Solid Organ Transplantation
Background: Respiratory viral infections are associated with increased pulmonary morbidity in immunocompromised populations. It is not known whether pediatric solid organ transplant (SOT) recipients who test positive for respiratory viruses prior to transplant have increased risk of adverse pulmonary outcomes. Methods: We conducted a single‐center retrospective study of pediatric SOT recipients tested for respiratory viruses by multiplex PCR in the 30 days prior to their transplant. Results: Fourteen of 45 recipients who were tested had a virus identified, one of whom tested negative on a subsequent repeat test prior to transplant. The remaining 13 were matched 1:2 to control transplant recipients matched by age at transplant, organ transplanted, and date of transplant. No differences in adverse pulmonary outcomes were identified up to 90 days post‐SOT. A similar comparison of patients testing positive to 31 patients with negative respiratory virus testing also did not identify any differences in adverse pulmonary outcomes. Conclusions: Among pediatric SOT recipients who underwent clinically indicated respiratory viral testing within 30 days prior to transplant, we did not observe a clear excess of post‐transplant pulmonary morbidity. Larger multicenter studies are needed to confirm this observation.
- Open Access
- 10 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (9)
Burden and Risk Factors for Severe Respiratory Syncytial Virus Infection among Pediatric Hematopoietic Cell Transplant Recipients
Background: Respiratory syncytial virus (RSV) causes substantial morbidity in pediatric hematopoietic cell transplant (HCT) recipients; however, risk factors for severe disease remain incompletely characterized. Methods: We conducted a multicenter retrospective cohort study across 16 U.S. transplant centers, evaluating children and adolescents (0–19 years) who underwent HCT and developed a laboratory-confirmed RSV infection between 2010 and 2019. Clinical characteristics, laboratory values, and immunosuppressive and transplant history were analyzed. Outcomes included new or increased supplemental oxygen requirement, RSV-related hospitalization, progression to lower respiratory tract infection (LRTI), invasive mechanical ventilation, and 90-day mortality. Univariate logistic regression was used to screen candidate predictors, followed by the least absolute shrinkage and selection operator for variable selection, and multivariable logistic regression to identify independent predictors associated with clinical outcomes. Results: Among 204 pediatric HCT recipients with RSV infection, 41.7% had RSV-related hospitalization, 21.2% required new or increased supplemental oxygen, and 4% required invasive mechanical ventilation within 28 days after the diagnosis. Mortality within 90 days was 5.4%, with one death attributable to RSV. In multivariable models, female sex, younger age (particularly <5 years), neutropenia (ANC <500/mm3), presence of co-pathogen in the respiratory tract and chronic lung disease were independently associated with this oxygen outcome, while non-peripheral graft sources and T-cell–depleting therapy were associated with RSV-related hospitalization. Conclusions: Severe outcomes are common in pediatric HCT recipients with RSV infection. Younger age, markers of impaired immune recovery, history of chronic lung disease, and T-cell–depleting therapy are major determinants of adverse outcomes. These findings support targeted risk stratification and may inform preventive and treatment strategies in this high-risk population.
- 10 September 2026
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 15 (9)
Open AccessBurden and Risk Factors for Severe Respiratory Syncytial Virus Infection among Pediatric Hematopoietic Cell Transplant Recipients
Background: Respiratory syncytial virus (RSV) causes substantial morbidity in pediatric hematopoietic cell transplant (HCT) recipients; however, risk factors for severe disease remain incompletely characterized. Methods: We conducted a multicenter retrospective cohort study across 16 U.S. transplant centers, evaluating children and adolescents (0–19 years) who underwent HCT and developed a laboratory-confirmed RSV infection between 2010 and 2019. Clinical characteristics, laboratory values, and immunosuppressive and transplant history were analyzed. Outcomes included new or increased supplemental oxygen requirement, RSV-related hospitalization, progression to lower respiratory tract infection (LRTI), invasive mechanical ventilation, and 90-day mortality. Univariate logistic regression was used to screen candidate predictors, followed by the least absolute shrinkage and selection operator for variable selection, and multivariable logistic regression to identify independent predictors associated with clinical outcomes. Results: Among 204 pediatric HCT recipients with RSV infection, 41.7% had RSV-related hospitalization, 21.2% required new or increased supplemental oxygen, and 4% required invasive mechanical ventilation within 28 days after the diagnosis. Mortality within 90 days was 5.4%, with one death attributable to RSV. In multivariable models, female sex, younger age (particularly <5 years), neutropenia (ANC <500/mm3), presence of co-pathogen in the respiratory tract and chronic lung disease were independently associated with this oxygen outcome, while non-peripheral graft sources and T-cell–depleting therapy were associated with RSV-related hospitalization. Conclusions: Severe outcomes are common in pediatric HCT recipients with RSV infection. Younger age, markers of impaired immune recovery, history of chronic lung disease, and T-cell–depleting therapy are major determinants of adverse outcomes. These findings support targeted risk stratification and may inform preventive and treatment strategies in this high-risk population.
- Open Access
- 20 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e858-e866
Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Background: Human adenovirus (HAdV) among pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients can result in asymptomatic infection with risk for disease progression. There are limited data defining HAdV infection, disease, and case-fatality rates in a HAdV polymerase chain reaction (PCR) surveillance testing era. The current study aimed to define these outcomes using a priori definitions applied by a central review committee. Methods: Pediatric allo-HCT recipients were followed up for 180 days after HCT at 10 pediatric institutions. Blood and stool specimens were collected 0–7 days prior to allo-HCT for serum HAdV immunoglobulin G and stool HAdV PCR testing. Clinical data, including HAdV PCR testing results, informed central review committee–designated outcomes of HAdV infection, including DNAemia, disease, and deaths (case-fatality rate). Outcomes were reported by HAdV surveillance testing status and by pretransplant research specimen results. Results: The cohort included 819 allo-HCT recipients; 649 (79.2%) were under HAdV surveillance. The HAdV infection and DNAemia incidence among surveilled patients was 27.1% and 16.0%, respectively. The incidence of proven or probable HAdV disease was 10.9% for the cohort and, 12.6% for those under surveillance. The HAdV infection incidence was highest (13 of 25 [52.0%]) in patients with pre-HCT HAdV immunoglobulin G and stool PCR positivity. The attributable case-fatality rate for those with proven or probable disease was 13.5%. Conclusions: HAdV infection and disease are common among pediatric allo-HCT recipients. HAdV disease is associated with a substantial HAdV-attributable mortality rate. Clinical trials assessing novel HAdV in pediatric allo-HCT recipients are needed. Pretransplant serology and stool PCR testing could identify high-risk patients for trial enrollment.
- 20 August 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (4) , e858-e866
Open AccessIncidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Background: Human adenovirus (HAdV) among pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients can result in asymptomatic infection with risk for disease progression. There are limited data defining HAdV infection, disease, and case-fatality rates in a HAdV polymerase chain reaction (PCR) surveillance testing era. The current study aimed to define these outcomes using a priori definitions applied by a central review committee. Methods: Pediatric allo-HCT recipients were followed up for 180 days after HCT at 10 pediatric institutions. Blood and stool specimens were collected 0–7 days prior to allo-HCT for serum HAdV immunoglobulin G and stool HAdV PCR testing. Clinical data, including HAdV PCR testing results, informed central review committee–designated outcomes of HAdV infection, including DNAemia, disease, and deaths (case-fatality rate). Outcomes were reported by HAdV surveillance testing status and by pretransplant research specimen results. Results: The cohort included 819 allo-HCT recipients; 649 (79.2%) were under HAdV surveillance. The HAdV infection and DNAemia incidence among surveilled patients was 27.1% and 16.0%, respectively. The incidence of proven or probable HAdV disease was 10.9% for the cohort and, 12.6% for those under surveillance. The HAdV infection incidence was highest (13 of 25 [52.0%]) in patients with pre-HCT HAdV immunoglobulin G and stool PCR positivity. The attributable case-fatality rate for those with proven or probable disease was 13.5%. Conclusions: HAdV infection and disease are common among pediatric allo-HCT recipients. HAdV disease is associated with a substantial HAdV-attributable mortality rate. Clinical trials assessing novel HAdV in pediatric allo-HCT recipients are needed. Pretransplant serology and stool PCR testing could identify high-risk patients for trial enrollment.
- Open Access
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0069926
Plasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults
Invasive fungal infection (IFI) is challenging to diagnose, often involving invasive sampling. Plasma cell-free metagenomic next-generation sequencing (mNGS) has shown promise in diagnosing infections, but data are limited on specific clinical scenarios in which this test is most helpful. We conducted a retrospective single-center study of children and young adults with high-risk conditions evaluated for IFI between December 2016 and November 2024. Clinical concern for IFI was indicated by (i) evaluation with both serum β-D-glucan and galactomannan testing, (ii) either or both of CT scans of sinuses and chest, and (iii) antifungal treatment either started or broadened. Episodes in which mNGS testing was sent within 30 days of initiation or broadening of antifungal coverage were evaluated to determine the diagnostic performance of mNGS testing, using EORTC-MSG criteria for proven or probable IFI as the comparator. We identified 227 episodes in 180 high-risk patients consistent with clinical concern for IFI. Of these, 45 episodes met EORTC-MSG criteria for proven/probable IFI. Plasma mNGS testing was sent in 36 episodes and identified the causative organism in 28. Positive and negative percent agreement for diagnosis of proven/probable IFI in this population was 77.8% and 90.4%, respectively. Among proven/probable cases with mNGS testing, Candida and Aspergillus were the most commonly identified fungi. Plasma mNGS testing in pediatric and young adult patients at risk for IFI compares favorably with diagnostic criteria used for IFI diagnosis and may be added to the diagnostic evaluation of patients at high-risk of IFI. IMPORTANCE: Performance of plasma mNGS testing for diagnosis of invasive fungal infection in high-risk pediatric and young adult patients was comparable to the combination of fungal culture and targeted PCR from invasively acquired samples, suggesting that it might allow earlier diagnosis for some patients.
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0069926
Open AccessPlasma metagenomic sequencing testing for diagnosis of invasive fungal infection in children and young adults
Invasive fungal infection (IFI) is challenging to diagnose, often involving invasive sampling. Plasma cell-free metagenomic next-generation sequencing (mNGS) has shown promise in diagnosing infections, but data are limited on specific clinical scenarios in which this test is most helpful. We conducted a retrospective single-center study of children and young adults with high-risk conditions evaluated for IFI between December 2016 and November 2024. Clinical concern for IFI was indicated by (i) evaluation with both serum β-D-glucan and galactomannan testing, (ii) either or both of CT scans of sinuses and chest, and (iii) antifungal treatment either started or broadened. Episodes in which mNGS testing was sent within 30 days of initiation or broadening of antifungal coverage were evaluated to determine the diagnostic performance of mNGS testing, using EORTC-MSG criteria for proven or probable IFI as the comparator. We identified 227 episodes in 180 high-risk patients consistent with clinical concern for IFI. Of these, 45 episodes met EORTC-MSG criteria for proven/probable IFI. Plasma mNGS testing was sent in 36 episodes and identified the causative organism in 28. Positive and negative percent agreement for diagnosis of proven/probable IFI in this population was 77.8% and 90.4%, respectively. Among proven/probable cases with mNGS testing, Candida and Aspergillus were the most commonly identified fungi. Plasma mNGS testing in pediatric and young adult patients at risk for IFI compares favorably with diagnostic criteria used for IFI diagnosis and may be added to the diagnostic evaluation of patients at high-risk of IFI. IMPORTANCE: Performance of plasma mNGS testing for diagnosis of invasive fungal infection in high-risk pediatric and young adult patients was comparable to the combination of fungal culture and targeted PCR from invasively acquired samples, suggesting that it might allow earlier diagnosis for some patients.
- Open Access
- 5 May 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (5) , e70204
Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population
Pentobarbital is a barbiturate with sedative and anticonvulsant properties, occasionally used in pediatric patients for preoperative sedation, deep sedation during mechanical ventilation, and seizure control. Despite its long‐standing clinical use, age‐appropriate dosing remains challenging due to variability across studies and limited pediatric pharmacokinetic (PK) data. This study (NCT01431326) aimed to characterize the population pharmacokinetics of pentobarbital in pediatric patients (birth to 21 years) and evaluate dosing strategies using model‐based simulations. A two‐compartment population PK model, allometrically scaled to total body weight, adequately described pentobarbital plasma concentrations, with no additional covariates identified as significant. Simulations were conducted across four age groups: 1 to <2 years, 2 to <6 years, 6 to <12 years, and 12 to <18 years. Comparable exposures were achieved across groups, although older and heavier patients tended to exhibit slightly higher exposures when non‐capped doses were applied. Based on simulation results, intravenous bolus doses of 1 mg/kg for preoperative sedation and 5 mg/kg followed by a continuous infusion of 1 mg/kg/h for seizure management appeared appropriate across the evaluated age range. For deep sedation, lower infusion rates (0.75 mg/kg/h) may be sufficient in older children (6 to 18 years) to match exposures observed in younger patients (1 to 6 years old) receiving 1 mg/kg/h. These findings support the currently recommended dosing regimens for pentobarbital in pediatric patients aged 1 to <18 years.
- 5 May 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (5) , e70204
Open AccessPopulation Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population
Pentobarbital is a barbiturate with sedative and anticonvulsant properties, occasionally used in pediatric patients for preoperative sedation, deep sedation during mechanical ventilation, and seizure control. Despite its long‐standing clinical use, age‐appropriate dosing remains challenging due to variability across studies and limited pediatric pharmacokinetic (PK) data. This study (NCT01431326) aimed to characterize the population pharmacokinetics of pentobarbital in pediatric patients (birth to 21 years) and evaluate dosing strategies using model‐based simulations. A two‐compartment population PK model, allometrically scaled to total body weight, adequately described pentobarbital plasma concentrations, with no additional covariates identified as significant. Simulations were conducted across four age groups: 1 to <2 years, 2 to <6 years, 6 to <12 years, and 12 to <18 years. Comparable exposures were achieved across groups, although older and heavier patients tended to exhibit slightly higher exposures when non‐capped doses were applied. Based on simulation results, intravenous bolus doses of 1 mg/kg for preoperative sedation and 5 mg/kg followed by a continuous infusion of 1 mg/kg/h for seizure management appeared appropriate across the evaluated age range. For deep sedation, lower infusion rates (0.75 mg/kg/h) may be sufficient in older children (6 to 18 years) to match exposures observed in younger patients (1 to 6 years old) receiving 1 mg/kg/h. These findings support the currently recommended dosing regimens for pentobarbital in pediatric patients aged 1 to <18 years.
- 19 April 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (4) , e70186
Population Pharmacokinetics and Exposure‐Safety Analysis of Furosemide in Preterm Infants
Furosemide is the most commonly used diuretic in preterm infants despite an incompletely understood relationship between dosing, exposure, and safety within this population. The goals of this study were to characterize furosemide population pharmacokinetics (popPK) in preterm infants and to evaluate safety by relating simulated furosemide exposure to events of ototoxicity, nephrocalcinosis, and nephrolithiasis. A total of 146 plasma furosemide concentrations from 51 preterm (23‐28.9 weeks’ gestational age) infants across two studies (one randomized, placebo‐controlled, dose‐escalating safety trial and one opportunistic, observational study) were included in the analysis. Standard nonlinear mixed effects popPK modeling techniques were applied. Exposure was simulated using the final popPK model (area under the curve) and Monte Carlo simulations (maximum concentration [C max ]). Logistic regression was used to evaluate the relationship between exposure and safety events. The final popPK model was a one‐compartment model with the covariates of weight on volume of distribution and both weight and post‐natal age on clearance. The model showed accurate predictions, adequate precision, and good model fit. Simulations indicated that furosemide 2 mg/kg administered enterally every 6 h would result in few (approximately 4%) C max values exceeding a 50 µg/mL threshold reported to be associated with treatment‐associated ototoxicity, and no more than 1% for all other dosing regimens. Events of hearing loss, nephrocalcinosis, or nephrolithiasis were rare and showed no relationship with furosemide exposure in logistic regression analysis. These data contributed to the October 2024 FDA label update to include pediatric popPK data and improve dosing in preterm infants.
- 19 April 2026
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (4) , e70186
Population Pharmacokinetics and Exposure‐Safety Analysis of Furosemide in Preterm Infants
Furosemide is the most commonly used diuretic in preterm infants despite an incompletely understood relationship between dosing, exposure, and safety within this population. The goals of this study were to characterize furosemide population pharmacokinetics (popPK) in preterm infants and to evaluate safety by relating simulated furosemide exposure to events of ototoxicity, nephrocalcinosis, and nephrolithiasis. A total of 146 plasma furosemide concentrations from 51 preterm (23‐28.9 weeks’ gestational age) infants across two studies (one randomized, placebo‐controlled, dose‐escalating safety trial and one opportunistic, observational study) were included in the analysis. Standard nonlinear mixed effects popPK modeling techniques were applied. Exposure was simulated using the final popPK model (area under the curve) and Monte Carlo simulations (maximum concentration [C max ]). Logistic regression was used to evaluate the relationship between exposure and safety events. The final popPK model was a one‐compartment model with the covariates of weight on volume of distribution and both weight and post‐natal age on clearance. The model showed accurate predictions, adequate precision, and good model fit. Simulations indicated that furosemide 2 mg/kg administered enterally every 6 h would result in few (approximately 4%) C max values exceeding a 50 µg/mL threshold reported to be associated with treatment‐associated ototoxicity, and no more than 1% for all other dosing regimens. Events of hearing loss, nephrocalcinosis, or nephrolithiasis were rare and showed no relationship with furosemide exposure in logistic regression analysis. These data contributed to the October 2024 FDA label update to include pediatric popPK data and improve dosing in preterm infants.
- Open Access
- 6 January 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 345
Correction: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity
- 6 January 2026
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 345
Open AccessCorrection: Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10‑Monohydroxy Derivative to Inform Dosing in Children with Obesity
- Open Access
- 17 November 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 329-344
Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity
Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.
- 17 November 2025
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 329-344
Open AccessPopulation Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity
Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.
- Open Access
- 29 September 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (2)
Physiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity
Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight. This study uses physiologically based pharmacokinetic (PBPK) modeling and leverages pharmacokinetic (PK) data acquired from children enrolled in pragmatic trials to understand dosing and subsequent exposure requirements in children with obesity. Drug concentrations of OXC and MHD (n = 148 each) from children with (n = 31) and without (n = 10) obesity, aged 2‐20 years, were collected from two clinical trials (NCT01431326 and NCT02993861) and used for external evaluation of a previously developed PBPK model of OXC using PK‐Sim. We used a previously published virtual population that accounts for the obesity‐related changes in physiology (e.g., liver size and glomerular filtration rate) in children for PK simulations in children with obesity. Model evaluation showed that ≥80% of MHD concentrations contributed by about two thirds of study subjects (26 out of 41) fell within the 90% prediction interval. The PBPK model showed that children with obesity had lower median (interquartile range) simulated weight‐normalized clearance (0.060 L/h/kg [0.048‐0.076 L/h/kg]) than children without obesity (0.067 L/h/kg [0.060‐0.077 L/h/kg]). Simulations revealed that the recommended pediatric dosing regimen produced comparable MHD exposure between children with and without obesity at steady state, supporting its applicability regardless of obesity status. This PBPK‐based dosing aligns with product label recommendations and demonstrates the potential of PBPK modeling for dosing other drugs in children with obesity.
- 29 September 2025
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 66 (2)
Open AccessPhysiologically Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize Its Disposition in Children with Obesity
Oxcarbazepine (OXC) is a second‐generation antiseizure medication, effective through its active metabolite, 10‐mono‐hydroxy derivative (MHD). OXC is used as adjunctive therapy for focal‐onset and primary generalized tonic–clonic seizures, with recommended dosing based on age and body weight. This study uses physiologically based pharmacokinetic (PBPK) modeling and leverages pharmacokinetic (PK) data acquired from children enrolled in pragmatic trials to understand dosing and subsequent exposure requirements in children with obesity. Drug concentrations of OXC and MHD (n = 148 each) from children with (n = 31) and without (n = 10) obesity, aged 2‐20 years, were collected from two clinical trials (NCT01431326 and NCT02993861) and used for external evaluation of a previously developed PBPK model of OXC using PK‐Sim. We used a previously published virtual population that accounts for the obesity‐related changes in physiology (e.g., liver size and glomerular filtration rate) in children for PK simulations in children with obesity. Model evaluation showed that ≥80% of MHD concentrations contributed by about two thirds of study subjects (26 out of 41) fell within the 90% prediction interval. The PBPK model showed that children with obesity had lower median (interquartile range) simulated weight‐normalized clearance (0.060 L/h/kg [0.048‐0.076 L/h/kg]) than children without obesity (0.067 L/h/kg [0.060‐0.077 L/h/kg]). Simulations revealed that the recommended pediatric dosing regimen produced comparable MHD exposure between children with and without obesity at steady state, supporting its applicability regardless of obesity status. This PBPK‐based dosing aligns with product label recommendations and demonstrates the potential of PBPK modeling for dosing other drugs in children with obesity.
- Open Access
- 13 May 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (5) , e70247
Physiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data
Children represent a highly complex and variable population for treatment, including interindividual differences in drug dose–exposure. Midazolam has been used as a sedative for hospitalized children on‐ and off‐label; however, factors affecting interindividual variability (IIV) in observed clearance for this population are not fully understood and can result in extreme under‐ or overexposure. Obesity has been described as a significant influence on midazolam in adolescents, which could potentially alter drug exposure. The goal of this study was to use two modeling strategies to evaluate dose–exposure of midazolam in children with and without obesity. Population pharmacokinetic modeling assessed whether measures of obesity status would explain some of the observed IIV for midazolam clearance. In all, 164 plasma concentrations were collected from 93 participating children, many with obesity. Covariate modeling did not identify any factors influential to clearance beyond body weight. Model IIV was similar to that observed in previous models of critically ill children (coefficient of variation, 175%) along with considerable residual unexplained variability (50.4%). Then, a previously published virtual population of children with obesity was incorporated into an existing physiologically based pharmacokinetic model of midazolam in the open‐source PK‐Sim software. Dosing simulations for a subset of 46 participants demonstrated minor overpredictions in children with obesity compared to those without. Both models predicted a minor (< 20%) increase in exposure for children with obesity given the same weight‐based dose. This research demonstrates the use of population pharmacokinetics combined with physiologically based pharmacokinetic modeling to compare simulated exposures in children with and without obesity.
- 13 May 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (5) , e70247
Open AccessPhysiologically Based and Population Pharmacokinetic Modeling of Midazolam in Children With Obesity Using Real‐World Data
Children represent a highly complex and variable population for treatment, including interindividual differences in drug dose–exposure. Midazolam has been used as a sedative for hospitalized children on‐ and off‐label; however, factors affecting interindividual variability (IIV) in observed clearance for this population are not fully understood and can result in extreme under‐ or overexposure. Obesity has been described as a significant influence on midazolam in adolescents, which could potentially alter drug exposure. The goal of this study was to use two modeling strategies to evaluate dose–exposure of midazolam in children with and without obesity. Population pharmacokinetic modeling assessed whether measures of obesity status would explain some of the observed IIV for midazolam clearance. In all, 164 plasma concentrations were collected from 93 participating children, many with obesity. Covariate modeling did not identify any factors influential to clearance beyond body weight. Model IIV was similar to that observed in previous models of critically ill children (coefficient of variation, 175%) along with considerable residual unexplained variability (50.4%). Then, a previously published virtual population of children with obesity was incorporated into an existing physiologically based pharmacokinetic model of midazolam in the open‐source PK‐Sim software. Dosing simulations for a subset of 46 participants demonstrated minor overpredictions in children with obesity compared to those without. Both models predicted a minor (< 20%) increase in exposure for children with obesity given the same weight‐based dose. This research demonstrates the use of population pharmacokinetics combined with physiologically based pharmacokinetic modeling to compare simulated exposures in children with and without obesity.